Medivation, Inc. was founded in 2003 and is based in San Francisco, California. Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of Alzheimer's disease, Huntington's disease, and castration-resistant prostate cancer. Its product pipeline includes Dimebon, which is in pivotal Phase 3 trial in patients with mild-to-moderate Alzheimer's disease, and is in Phase 2 clinical trial in patients with mild-to-moderate Huntington's disease; and MDV3100, a Phase 1-2 clinical trial product in patients with castration-resistant prostate cancer. The company has a collaboration agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases, as well as an agreement to develop and commercialize MDV3100, an investigational drug for the treatment of prostate cancer.

Eurand, Inc. company, a subsidiary of Netherlands-based Eurand N.V., develops drug delivery technologies to help drugmakers improve the efficacy of their products. Eurand researches and manufactures drugs marketed in the Americas and Europe, mostly through partnerships with other pharma companies. Eurand's drug delivery systems include Biorise to make certain drugs water soluble; Diffucaps and Minitabs to control the release of drug components as they make their way through the digestive system; and AdvaTab and Liquitard to mask the taste of medicines. The company also conducts research for its parent's own portfolio of drugs under development.

The Wellcome Trust Sanger Institute (Sanger Institute) is a leading research center dedicated to analyzing and understanding genomics. Best known for its work on the Human Genome Project (the institute is responsible for sequencing one-third of the human genome), the Sanger Institute is applying genomics to the study of organisms that cause diseases such as malaria, typhoid, and tuberculosis. The institute was founded in 1993 by the Wellcome Trust and the Medical Research Council, and has been funded by a $430 million grant from the Wellcome Trust since 2001.

Lipoxen Plc, a biopharmaceutical company, develops drug and vaccine delivery systems, and proprietary products in the fields of protein drugs, vaccines, and oncology. The company’s product candidates under development include ErepoXen for the treatment to maintain the red blood cell population and prevent anaemia; StimuXen for the treatment of neutropenia; InferoXen for hepatitis C; SuliXen for the treatment of type II diabetes; LipoNeu for streptococcus pneumoniae; LipoTet, an oral liposomal tetanus vaccine; HepaXen to prevent and treat hepatitis B; LipoRab, a rabies vaccine candidate; and LipoTaxen, an anti-cancer drug for the treatment of lung, breast, ovarian, and other cancers. It has operations in the United States, Europe, and India. Lipoxen Plc has a collaboration agreement with Pharmsynthez JSC. The company is based in London, the United Kingdom.

Onyx Pharmaceuticals was founded in 1992 and is headquartered in Emeryville, California. Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally. Its lead product includes Nexavar (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in tumor cell proliferation and angiogenesis. This product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals. The company is also conducting various ongoing trials on Nexavar for conditions, such as non-small cell lung cancer, melanoma, breast cancer, and other cancers. It also develops ONX 0801, an oncology compound in preclinical development stage, under a development and license agreement with BTG International Limited. In addition, Onyx Pharmaceuticals, through a development collaboration, option, and license agreement with S*BIO Pte Ltd, owns options to license the rights of ONX 0803 and ONX 0805. ONX 0803 is an orally available, potent, and selective inhibitor of JAK2; and ONX 0805 is a JAK2 inhibitor. Further, the company has a research and development collaboration agreement with Warner-Lambert Company to discover and commercialize small molecule drugs that restore the control of, or otherwise intervene in, the misregulated cell cycle in tumor cells.

Pro-Pharmaceuticals, Inc. is a development-stage company engaged in the discovery and development of carbohydrate-based therapeutics. The Company’s therapeutics is used in treatment of liver, microbial and inflammatory diseases. All of its products were in development, including pre-clinical and clinical trials during the year ended December 31, 2008. The Company focuses on the development of a new generation of anti-cancer treatments using carbohydrate polymers to increase survival and improve the quality of life for cancer patients. Its principal pipeline candidate, DAVANAT, is a chemical entity that is in Phase II trials for first-line treatment of colorectal and biliary cancer. In September 2008, the Company submitted a clinical and pre-clinical package to the United States Food and Drug Administration (FDA) in support of its DAVANAT New Drug Application (NDA).

CyBio just might supplant the underpaid laboratory research assistant, so efficient are its automated systems; in all, the company makes it easier for laboratory scientists to focus on research and less on the repetitive processes involved therein. CyBio develops, produces, and markets technology platforms for drug discovery. With more than 15 years of experience in the field, CyBio provides the tools for pharmaceutical and agrochemical research, including pipetting instruments for liquid handling, incubating, and replicating, as well as software and system integration, for automated screening and reading.

DARA BioSciences, Inc. (DARA), formerly Point therapeutics, Inc. is a development stage pharmaceutical company that acquires therapeutic molecules and medical technologies from third parties, and advances their clinical development for later sale to pharmaceutical and biotechnology companies. DARA focuses on two drug development programs: KRN5500 for neuropathic pain in cancer patients and DB959 for type 2 diabetes. On February 12, 2008, Point and DARA BioSciences, Inc. completed their merger transaction, in which DP Acquisition Corp. (a wholly owned subsidiary of Point) merged with and into DARA BioSciences, Inc.

Isis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Isis Pharmaceuticals, Inc., through its drug discovery platform based on antisense technology, discovers and develops drugs that bind to RNA antisense technology. The company has commercialized its antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. It licenses its drugs to partners prior to late-phase development and commercialization. The company and Alnylam Pharmaceuticals jointly own Regulus Therapeutics Inc., a company focused on the discovery, development, and commercialization of microRNA therapeutics. Isis is the owner or exclusive licensee of approximately 1,600 issued patents worldwide.

China DongSheng International manufactures nutritional supplements and air purifiers. Founded in 1991 as PaperClip Imaging Software, the company's original business was document management software development. After a 2006 reverse merger with American Sunrise International (the holding company of China-based Jilin Dongsheng Weiye Science & Technology Development Co.), the company changed its name to China DongSheng International and shifted its focus to natural health supplements and purifiers. Now generating the majority of its revenues from its new lines, China DongSheng plans to spin off its PaperClip operations.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.